(Q64047828)
Statements
An Extension of the 6-month, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study Comparing Efficacy and Safety of FTY720 0.5 mg and 1.25 mg Administered Orally Once Daily in Patients With Relapsing Multiple Sclerosis (English)
0 references
April 2008
0 references
April 2012
0 references
143
0 references
18 year
0 references
60 year
0 references